

APPLICATION FOR
UNITED STATES LETTERS PATENT
IN THE
UNITED STATES PATENT AND TRADEMARK OFFICE

(Case No. HYZ-069)

Title:

NOVEL HIV-SPECIFIC SYNTHETIC OLIGONUCLEOTIDES
AND METHODS OF THEIR USE

Inventor:

Sudhir Agrawal

Assignee:

HYBRIDON, INC.
A Corporation of the State of Delaware

09896692 * 098961

NOVEL HIV-SPECIFIC SYNTHETIC OLIGONUCLEOTIDES
AND METHODS OF THEIR USE

5 BACKGROUND OF THE INVENTION

10 This invention relates to the treatment of HIV infection. More particularly, this invention relates to synthetic modified antisense oligonucleotides and pharmaceutical compositions containing such oligonucleotides and to methods of inhibiting HIV replication and treating HIV infection using such oligonucleotides.

15 Human immunodeficiency virus types 1 and 2 (HIV-1, HIV-2), formerly called human T-cell leukemia lymphotropic virus-type III (HTLV-III), are believed to be the etiological agents of acquired immune deficiency syndrome (AIDS). HIV 20 is part of the *Retroviridae* family, the members of which contain an RNA genome and reverse transcriptase activity. During their growth cycle, retroviruses copy their RNA into proviral DNA. The proviral DNA is able to integrate into 25 the chromosomal DNA of the host cell where it uses the transcriptional and translational machinery of the host to express viral RNA and proteins. Viruses are released from the cell by budding from 30 the cytoplasmic membrane. In the case of HIV-1 and HIV-2, viral replication results in the death of helper T-cell host cells, which leads to a state of severe immunodeficiency, to the development of various malignancies and 35 opportunistic infections, and ultimately to the death of the infected organism.

01-05866532-662901

The incidence of AIDS has risen to epidemic proportions in many countries without the development of preventative treatments or therapies which are successful in the long term.

5 Those few therapeutic agents which have been prescribed, such as the nucleoside analogs 3'-azido-3'-deoxythymidine (AZT), dideoxyinosine (ddI), and dideoxycytosine (ddC), and various protease inhibitors have met with limited success.

10 This has been in part because of the cytotoxicity of these agents. In addition, some viruses escape due to mutations that render them insensitive to these agents and the difficulty of antiviral action due to the ability of the virus to

15 integrate into the host's genome. Thus, there is a long felt need for more effective therapeutic agents and preventative therapies for AIDS.

20 More recently new chemotherapeutic agents have been developed which are capable of modulating cellular and foreign gene expression. These agents, called antisense oligonucleotides, bind to a target single-stranded nucleic acid molecules according to the Watson-Crick or the

25 Hoogstein rule of base pairing, and in doing so, disrupt the function of the target by one of several mechanisms: by preventing the binding of factors required for normal translation or transcription; in the case of an mRNA target, by

30 triggering the enzymatic destruction of the message by RNase H; or by destroying the target via reactive groups attached directly to the antisense oligonucleotide.

Antisense oligodeoxynucleotides have been
designed to specifically inhibit the expression of
HIV-1 and other viruses (see, e.g., Agrawal (1992)
Trends in Biotechnology 10:152-158; Agrawal et al. in
5 *Gene Regulation: Biology of Antisense RNA and DNA* (Erickson
and Izant, eds.) Raven Press Ltd., New York (1992)
pp. 273-283); Matsukura et al. in *Prospects for Antisense
Nucleic Acid Therapy of Cancer and AIDS*, Wiley-Liss, Inc.
(1992) pp. 159-1798; and Agrawal (1991) in
10 *Prospects for Antisense Nucleic Acid Therapy for Cancer and AIDS*,
(Wickstrom, ed.) Liss, New York, pp. 145-148).
For example, it has been shown that antisense
oligonucleotides having phosphodiester
15 internucleoside bonds and sequences complementary
to portions of genomic HIV-1 RNA inhibit viral
replication in early infected cells (Zamecnik et
al. (1986) *Proc. Acad. Sci. USA* 83:4143-4147; Goodchild
et al. (1988) *Proc. Natl. Acad. Sci USA* 85:5507-5511).

20 However, these phosphodiester-linked
molecules are less able to inhibit viral
replication in chronically infected cells (Agrawal
et al. (1989) *Proc. Natl. Acad. Sci USA* 86:7790-7794),
mainly because of their nuclease susceptibility
25 (Wickstrom (1986) *J. Biochem. Biophys. Meth.* 13:97-102).
Therefore, chemically modified, nuclease-resistant
analogs have been developed which are effective in
inhibiting HIV-1 replication in tissue cultures
(see, Sarin et al. (1988) *Proc. Natl Acad. Sci. USA*
30 85:7448-7451; Agrawal et al. (1988) *Proc. Natl Acad. Sci
USA* 85:7079-7083; Matsukura et al. (1988) *Gene*
72:343-347). These analogs include

oligonucleotides with nuclease-resistant phosphorothioate internucleotide linkages shown to inhibit HIV-1 replication in both acute infection (U.S.S.N. 08/309,823; Agrawal et al. (1989) *Proc. Natl. Acad. Sci USA* 86:7790-7794) and in chronically infected cell lines (Agrawal et al. (1991) in *Gene Regulation: Biology of Antisense RNA*, eds. Erickson et al. (Raven Press, New York), pp. 273-284; Vickers et al. (1991) *Nucleic Acids Res.* 19:3359-3368; Matsukura et al. (1989) *Proc. Natl Acad. Sci.* 86:4244-4248; Agrawal et al. (1988) *Proc. Natl Acad. Sci USA* 85:7079-7083).

However, some phosphorothioate-linked oligonucleotides that have "GC-rich" nucleotide sequences have been found to evoke immunostimulatory responses in the organisms to whom they have been administered. For example, Kniep et al. (*Nature* (1995) 374:546-549) discloses that oligonucleotides containing the CG dinucleotide flanked by certain other sequences have a mitogenic and other side effects.

Thus, there still remains a need for a more effective anti-HIV oligonucleotide having therapeutic effects that are accompanied fewer side effects, e.g., little cellular toxicity and reduced immunostimulatory response.

SUMMARY OF THE INVENTION

It has been discovered that synthetic oligonucleotides directed to a region of the HIV 5 *gag* inhibit HIV-1 and HIV-2 infection of mammalian cells. These discoveries have been exploited to develop the present invention, which in its broadest aspect, provides synthetic oligonucleotides having a nucleotide sequence 10 specifically complementary to nucleotides 325 to 346 of a conserved *gag* region of the HIV genome set forth as SEQ ID NO:3. These oligonucleotides have 21 nucleotides ("21mers") which are linked via phosphorothioate internucleotide linkages. 15 Such phosphorothioate linkages contain a substitution of sulfur for oxygen, thereby rendering the oligonucleotide resistant to nucleolytic degradation. The phosphorothioate linkages may be mixed R_p and S_p enantiomers, or they may be stereoregular or substantially 20 stereoregular in either R_p or S_p form (see Iyer et al. (1995) *Tetrahedron Asymmetry* 6:1051-1054).

As used herein, the term "synthetic 25 oligonucleotide" includes chemically synthesized polymers of 12 to 50, preferably from about 15 to about 30, and most preferably, 21 ribonucleotide and/or deoxyribonucleotide monomers connected together or linked by at least one, and preferably 30 more than one, 5' to 3' internucleotide linkage. The term "nucleotide sequence specifically complementary to" nucleotides 324 to 345 of a conserved *gag* region of the HIV genome is intended to mean a sequence of nucleotides that binds to

the *gag* genomic RNA, proviral DNA, or mRNA sequence under physiological conditions, e.g., by Watson-Crick base pairing (interaction between oligonucleotide and single-stranded nucleic acid) 5 or by Hoogsteen base pairing (interaction between oligonucleotide and double-stranded nucleic acid) or by any other means including in the case of a oligonucleotide binding to RNA, causing pseudoknot formation. Binding by Watson-Crick or Hoogsteen 10 base pairing under physiological conditions is measured as a practical matter by observing interference with the function of the nucleic acid sequence. The term "a conserved *gag* region" refers to a sequence of nucleotides within the 15 *gag* gene which is found in related HIV strains.

In one embodiment, the oligonucleotides of the invention comprise at least two 3'-terminal ribonucleotides, at least two 5'-terminal ribonucleotides, or at least two 3'-terminal and 20 at least two 5' terminal ribonucleotides. In preferred embodiments according to this aspect of the invention, the oligonucleotide is a core region hybrid oligonucleotide comprising a region 25 of at least two deoxyribonucleotides, flanked by 5' and 3' ribonucleotide regions, each having at least two ribonucleotides. In one particular embodiment, the oligonucleotides of the invention have four contiguous 3'-terminal ribonucleotides, 30 and four contiguous 3'-terminal ribonucleotides, flanking 13 deoxynucleotides.

In preferred embodiments, the ribonucleotides in the hybrid oligonucleotide are 2'-substituted

ribonucleotides. For purposes of the invention, the term "2'-substituted" means substitution of the 2' position of the pentose moiety with an -O- lower alkyl group containing one to six saturated or unsaturated carbon atoms, or with an -O-aryl or allyl group having two to six carbon atoms, wherein such alkyl, aryl or allyl group may be unsubstituted or may be substituted, e.g., with halo, hydroxy, trifluoromethyl, cyano, nitro, acyl, acyloxy, alkoxy, carboxyl, carbalkoxyl, or amino groups; or with a hydroxy, an amino or a halo group, but not with a 2'-H group. In specific embodiments, the ribonucleotides are 2'-O-alkyl ribonucleotides such as 2'-O-methyl ribonucleotides.

In particular embodiments, the oligonucleotides of the invention have SEQ ID NO:1, NO:2, NO:3, or NO:4. In some embodiments, these oligonucleotides inhibit HIV-1 or HIV-2 infection in a cell and/or exhibit antiviral activity against HIV-1 and HIV-2.

In yet another aspect, the invention provides pharmaceutical formulations suitable for inhibiting and treating HIV-1 or HIV-2 infection and having reduced side effects such as immunogenicity. These formulations and for inhibiting comprising at least one oligonucleotide in accordance with the invention in a pharmaceutically acceptable carrier.

As used herein, a "pharmaceutically or physiologically acceptable carrier" includes any

and all solvents (including but limited to lactose), dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use
5 of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions of the
10 invention is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

In another aspect, the invention provides a
15 method of treating HIV-1 or HIV-2 infection in a mammal. In this method an oligonucleotide according to the invention is administered to the mammal in an amount effective to inhibit the proliferation of the virus. For purposes of the
20 invention, the term "mammal" is meant to encompass primates and humans. In some embodiments, the oligonucleotide is orally administered to the mammal. The term "orally administered" refers to the provision of the formulation via the mouth
25 through ingestion, or via some other part of the gastrointestinal system including the esophagus. In other embodiments, the oligonucleotide is administered via intravenous injection. In yet other embodiments, the oligonucleotide is
30 administered colorectally. The term "colorectal administration" or "rectal administration" or "colorectally administered" refers to the provision of the pharmaceutical formulation of the invention to any part of the large intestine via

surgical implantation, anal administration, or any other mode of placement therein.

5 The invention also provides in another aspect a method of inhibiting HIV-1 or HIV-2 infection in a cell. In this method the cell is contacted with a synthetic oligonucleotide according to the invention.

10 In yet another aspect, the invention provides
a method for introducing an intact oligonucleotide
into a mammal. This method comprises
administering to the mammal an oligonucleotide
according to the invention which is present in
15 intact form in the systemic plasma of the mammal
following oral administration. In one embodiment,
the oligonucleotide is orally or enterally
administered. In another embodiment, the
oligonucleotide is intravenously administered.

BRIEF DESCRIPTION OF THE DRAWINGS

5 The foregoing and other objects of the present invention, the various features thereof, as well as the invention itself may be more fully understood from the following description, when read together with the accompanying drawings in which:

10 FIG. 1 is a graphic representation of the inhibition of HIV-1 infection in cells treated during initial infection with a 4X4 hybrid oligonucleotide of the invention having SEQ ID NO:1;

15 FIG. 2 is a graphic representation of the inhibition of HIV-1 infection in cells treated following initial infection with a 4X4 hybrid oligonucleotide of the invention having SEQ ID NO:1; and

20 FIG. 3 is a graphic representation of the results of an XTT assay demonstrating the ability of a 4x4 oligonucleotide of the invention having SEQ ID NO:1 to inhibit HIV-2-induced cell killing.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

5 The patent and scientific literature referred to herein establishes the knowledge that is available to those with skill in the art. The issued U.S. patent, allowed patent applications, and articles cited herein are hereby incorporated by reference.

10 It is known that antisense oligonucleotides, can bind to a target single-stranded nucleic acid molecule according to the Watson-Crick or the Hoogsteen rule of base pairing, and in doing so, disrupt the function of the target by one of 15 several mechanisms: by preventing the binding of factors required for normal transcription, splicing, or translation; by triggering the enzymatic destruction of mRNA by RNase H if a contiguous region of deoxyribonucleotides exists 20 in the oligonucleotide, and/or by destroying the target via reactive groups attached directly to the antisense oligonucleotide.

25 Novel antisense oligonucleotides have been designed which inhibit HIV-1 and HIV-2 replication. These oligonucleotides are synthetic oligonucleotides having phosphorothioate internucleotide linkages and a nucleotide sequence that is complementary to a portion of the *gag* 30 region of the genome of HIV-1 and HIV-2. Sequences situated in this region have been demonstrated to be essential for viral packaging. These sequences form a stable secondary structure (Harrison et al. (1991) in *RNA Tumor Viruses* (Coffin

et al., eds.) Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp. 235). The oligonucleotides of the invention have been designed to bind to this region of RNA and DNA, thereby disrupting its natural stability and resulting ultimately in the inhibition of viral packaging and translation of *gag* mRNA. The specific sequence to which the oligonucleotides of the invention are complementary is nucleotides 324-345 of the *gag* region of HIV-1. This sequence is very conserved among strains of HIV-1, as shown below in TABLE 1.

TABLE 1

| | | | | |
|----|--------------|--|-----------|--------|
| 15 | Sequence of: | | | |
| | 324-345→ | TCTTCCTCTCTACCCACGCT | | |
| | CONSENSUS | CGGAGGCTAGAAGGAGAGATGGGTGCGAGACGTCAGTA | . | . |
| 20 | Strains | . | . | . |
| | of HIV-1 | . | . | . |
| | HTLV/LLAV | G | | A |
| | HIVLAI | G | | A |
| | HIVNL43 | G | | G |
| | HIVMN | G | | G |
| 25 | HIVJH3 | G | | A |
| | HIVOYI | G | | A |
| | HIVCDC4 | G | | A |
| | HIVRF | G | | A |
| | HIVMAL | G | | A |
| 30 | | . | (African) | |
| | HIVU455 | A | A | CCTCAG |
| | | | (Ugandan) | |
| 35 | HIVSF2 | (GA) | 4G | G |
| | HIVNDK | | G | A |

Targeting an antisense oligonucleotide to such a conserved region including an active gene allows for efficient inhibition of HIV proliferation without the generation of "escape 5 mutants." Escape mutants arise when a mutation occurs in a region of the genome targeted by the antisense oligonucleotide. They occur at a higher frequency in non-coding regions (like the SA 10 region of HIV-1) than in regions encoding a protein.

Oligonucleotides of the invention are more specific, less toxic, and have greater nuclease 15 resistance than many other chemotherapeutic agents designed to inhibit HIV replication. In particular, these oligonucleotides are less immunostimulatory than other oligonucleotides directed to the HIV-1 *gag* sequence because their nucleotide sequences are not GC-rich. 20 Furthermore, these hybrid oligonucleotides having phosphorothioate linkages are more resistant to nucleolytic degradation than are DNA compounds having solely phosphodiester linkages.

25 The oligonucleotides useful in the method of the invention are at least 12 nucleotides in length, but are preferably 15 to 21 nucleotides long, with 21mers being most common. They are 30 composed of deoxyribonucleotides, ribonucleotides, or a combination of both (i.e., are "hybrids"), with the 5' end of one nucleotide and the 3' end of another nucleotide being covalently linked by phosphorodithioates or phosphorothioates, non-

phosphodiester internucleotide linkages. Oligonucleotides with these linkages can be prepared according to known methods such as phosphoramidate or H-phosphonate chemistry which 5 can be carried out manually or by an automated synthesizer as described by Brown (*A Brief History of Oligonucleotide Synthesis. Protocols for Oligonucleotides and Analogs, Methods in Molecular Biology* (1994) 20:1-8). (See also, e.g., Sonveaux "Protecting Groups in 10 Oligonucleotides Synthesis" in Agrawal (1994) *Methods in Molecular Biology* 26:1-72; Uhlmann et al. (1990) *Chem. Rev.* 90:543-583).

15 The oligonucleotides of the composition may also be additionally modified in a number of ways without compromising their ability to hybridize to the target nucleic acid. Such modifications include, for example, those which are internal or at the end(s) of the oligonucleotide molecule and 20 include additions to the molecule of the internucleoside phosphate linkages, such as cholesteryl or diamine compounds with varying numbers of carbon residues between the amino groups and terminal ribose, deoxyribose and phosphate modifications which cleave, or crosslink to the opposite chains or to associated enzymes or other proteins which bind to the viral genome. Examples of such modified oligonucleotides include 25 oligonucleotides with a modified base and/or sugar such as arabinose instead of ribose, or a 3', 5'-substituted oligonucleotide having a sugar which, at both its 3' and 5' positions is attached to a chemical group other than a hydroxyl group (at its 30

3' position) and other than a phosphate group (at its 5' position). Other modified oligonucleotides are capped with a nuclease resistance-conferring bulky substituent at their 3' and/or 5' end(s) ,
5 or have a substitution in one nonbridging oxygen per nucleotide. Such modifications can be at some or all of the internucleoside linkages, as well as at either or both ends of the oligonucleotide and/or in the interior of the molecule. For the
10 preparation of such modified oligonucleotides, see, e.g., Agrawal (1994) *Methods in Molecular Biology* 26; Uhlmann et al. (1990) *Chem. Rev.* 90:543-583). Oligonucleotides which are self-stabilized are also considered to be modified oligonucleotides
15 useful in the methods of the invention (Tang et al. (1993) *Nucleic Acids Res.* 20:2729-2735). These oligonucleotides comprise two regions: a target hybridizing region; and a self-complementary region having an oligonucleotide sequence complementary to a nucleic acid sequence that is
20 within the self-stabilized oligonucleotide.

The preparation of these unmodified and modified oligonucleotides is well known in the art (reviewed in Agrawal et al. (1992) *Trends Biotechnol.* 10:152-158; see, e.g., Uhlmann et al. (1990) *Chem. Rev.* 90:543-584; and (1987) *Tetrahedron Lett.* 28:(31):3539-3542); Agrawal (1994) *Methods in Molecular Biology* 20:63-80); and Zhang et al. (1996) *J. Pharmacol. Expt. Thera.* 278:1-5).

Preferred oligonucleotides according to the invention are hybrid oligonucleotides in that they

contain both deoxyribonucleotides and at least two 2' substituted ribonucleotides at their termin(i/us). For purposes of the invention, the term "2'-substituted" means substitution at the 2' position of the ribose with, e.g., a -O-lower alkyl containing 1-6 carbon atoms, aryl or substituted aryl or allyl having 2-6 carbon atoms e.g., 2'-O-allyl, 2'-O-aryl, 2'-O-alkyl, 2'-halo, or 2'-amino, but not with 2'-H, wherein allyl, aryl, or alkyl groups may be unsubstituted or substituted, e.g., with halo, hydroxy, trifluoromethyl, cyano, nitro, acyl, acyloxy, alkoxy, carboxyl, carbalkoxyl or amino groups. Useful substituted ribonucleotides are 2'-O-alkyls such as 2'-O-methyl, 2'-O-ethyl, and 2'-O-propyl, with 2'-O-methyl being the most preferred.

The hybrid oligonucleotides useful in the method of the invention resist nucleolytic degradation, form stable duplexes with RNA or DNA, and preferably activate RNase H when hybridized with RNA. They may additionally include at least one unsubstituted ribonucleotide. For example, an oligonucleotide useful in the method of the invention may contain all deoxyribonucleotides with the exception of two 2' substituted ribonucleotides at the 3' terminus of the oligonucleotide, or the 5' terminus of the oligonucleotide. Alternatively, the oligonucleotide may have at least two, and preferably 4, substituted ribonucleotides at both its 3' and 5' termini.

Preferred oligonucleotides have at least two and preferably four 2'-0-methyl ribonucleotides at both the 3' and 5' termini, with the remaining nucleotides being deoxyribonucleotides. One
5 preferred oligonucleotide is a 21mer phosphorothioate linked oligonucleotide containing therein deoxyribonucleotides flanked on each side by four 2'-0-methyl ribonucleotides. This preferred oligonucleotide is referred to as a
10 "4x4". One preferred class of oligonucleotides useful in the method of the invention contains four or more deoxyribonucleotides in a contiguous block, so as to provide an activating segment for RNase H. In certain cases, more than one such
15 activating segment will be present at any location within the interior of the oligonucleotide. There may be a majority of deoxyribonucleotides in oligonucleotides according to the invention. In fact, such oligonucleotides may have as many as
20 all but two nucleotide being deoxyribonucleotides.

TABLE 2 lists some representative species of oligonucleotides which are useful in the method of the invention. 2'-substituted nucleotides are
25 underscored.

TABLE 2

| 30 | OLIGO NO. | OLIGONUCLEOTIDE (5'-3') | SEQ ID NO: |
|----|--------------|-------------------------------|---------------|
| | 1 | UCGCACCC <u>ATCTCTCTCCUUC</u> | 1 |
| | 2 | UCGCACCC <u>ATCTCTCTCCUUC</u> | 1 |
| 35 | 3 | UCGCACCC <u>ATCTCTCTCCUUC</u> | 1 |
| | 4 | UCGCACCC <u>ATCTCTCTCCUUC</u> | 1 |

TABLE 2 (cont.)

| | | | |
|----|----|-----------------------------------|---|
| | 5 | <u>UCGCACCCATCTCT<u>CCUUC</u></u> | 1 |
| | 6 | <u>UCGCACCCATCTCT<u>CCUUC</u></u> | 1 |
| 5 | 7 | <u>UCGCACCCATCTCT<u>CCUUC</u></u> | 1 |
| | 8 | <u>UCGCACCCATCTCT<u>CCUUC</u></u> | 1 |
| | 9 | <u>UCGCACCCATCTCT<u>CCUUC</u></u> | 1 |
| | 10 | <u>UCGCACCCATCTCT<u>CCUUC</u></u> | 1 |
| | 11 | <u>UCGCACCCATCTCT<u>CCUUC</u></u> | 1 |
| 10 | 12 | <u>UCGCACCCATCTCT<u>CCUUC</u></u> | 1 |
| | 13 | <u>UCGCACCCATCTCT<u>CCUUC</u></u> | 1 |
| | 14 | <u>UCGCACCCATCTCT<u>CCUUC</u></u> | 1 |
| | 15 | <u>UCGCACCCATCTCT<u>CCUUC</u></u> | 1 |
| | 16 | <u>UCGCACCCATCTCT<u>CCUUC</u></u> | 1 |
| 15 | 17 | <u>UCGCACCCATCTCT<u>CCUUC</u></u> | 1 |
| | 18 | <u>UCGCACCCATCTCT<u>CCUUC</u></u> | 1 |
| | 19 | <u>UCGCACCCATCTCT<u>CCUUC</u></u> | 1 |
| | 20 | TCGCACCCATCTCT <u>CCCTTC</u> | 2 |
| | 21 | CGCACCCATCTCT <u>CCUUCU</u> | 3 |
| 20 | 22 | CGCACCCATCTCT <u>CCUUCU</u> | 3 |
| | 23 | CGCACCCATCTCT <u>CCUUCU</u> | 3 |
| | 24 | CGCACCCATCTCT <u>CCUUCU</u> | 3 |
| | 25 | CGCACCCATCTCT <u>CCUUCU</u> | 3 |
| | 26 | <u>CGCACCCATCTCT<u>CCUUCU</u></u> | 3 |
| 25 | 27 | <u>CGCACCCATCTCT<u>CCUUCU</u></u> | 3 |
| | 28 | <u>CGCACCCATCTCT<u>CCUUCU</u></u> | 3 |
| | 29 | <u>CGCACCCATCTCT<u>CCUUCU</u></u> | 3 |
| | 30 | <u>CGCACCCATCTCT<u>CCUUCU</u></u> | 3 |
| | 31 | <u>CGCACCCATCTCT<u>CCUUCU</u></u> | 3 |
| 30 | 32 | <u>CGCACCCATCTCT<u>CCUUCU</u></u> | 3 |
| | 33 | <u>CGCACCCATCTCT<u>CCUUCU</u></u> | 3 |
| | 34 | <u>CGCACCCATCTCT<u>CCUUCU</u></u> | 3 |
| | 35 | <u>CGCACCCATCTCT<u>CCUUCU</u></u> | 3 |
| | 36 | <u>CGCACCCATCTCT<u>CCUUCU</u></u> | 3 |

TABLE 2 (cont.)

| | | |
|------|-----------------------------|---|
| 37 | <u>CGCACCCATCTCTCCUUCU</u> | 3 |
| 38 | <u>CGCACCCATCTCTCCUUCU</u> | 3 |
| 5 39 | <u>CGCACCCATCTCTCCUUCU</u> | 3 |
| 40 | <u>CGCACCCATCTCTCCCTTCT</u> | 4 |

10 Oligonucleotides as described above are
useful in a method of inhibiting HIV-1 or HIV-2
infection in a cell. In this method a cell is
contacted with an oligonucleotide of the invention
such that virus present in the cell at the time of
15 contact, or after such contact is unable to
replicate.

20 To determine whether oligonucleotides of the
invention could inhibit or prevent HIV infection,
cytopathic effect- (CPE-)based infection
experiments were performed in MT-4 cells. The
results of these studies indicate that
oligonucleotides of the invention can both inhibit
25 an existing infection (FIG. 1) and protect against
such infection (FIG. 2).

30 In addition, it was determined that synthetic
oligonucleotides systemically administered to
pregnant murine females crossed the placenta and
became available in the blood of embryos *in utero*.
Thus, it is contemplated that oligonucleotides of
the invention will be used in a method of treating
the fetuses and human mothers harboring HIV.

06866666-062931

The oligonucleotides described herein are administered to the mammal in the form of therapeutic pharmaceutical formulations that are effective for treating virus infection. These 5 pharmaceutical formulation may be administered in conjunction with other therapeutic agents, e.g., AZT and/or various protease inhibitors, to treat AIDS.

10 The therapeutic pharmaceutical formulation containing at least one oligonucleotide according to the invention includes a physiologically acceptable carrier which is congruent with the mode of administration. Examples include an inert diluent or an assimilable edible carrier. Suitable formulations that include 15 pharmaceutically acceptable excipients for introducing compounds to the bloodstream by intravenous injection and other than injection routes can be found in *Remington's Pharmaceutical Sciences* (18th ed.) (Genarro, ed. (1990) Mack Publishing Co., Easton, PA).

20 The pharmaceutical forms suitable for 25 injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile. It must be stable under the 30 conditions of manufacture and storage and may be preserved against the contaminating action of microorganisms, such as bacterial and fungi. The carrier can be a solvent or dispersion medium. The prevention of the action of microorganisms can

be brought about by various antibacterial and antifungal agents. Prolonged absorption of the injectable therapeutic agents can be brought about by the use of the compositions of agents delaying absorption. Sterile injectable solutions are prepared by incorporating the oligonucleotide in the required amount in the appropriate solvent, followed by filtered sterilization.

10 Alternatively, the oligonucleotide of the invention and other ingredients may be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the individual's diet. The oligonucleotide may be
15 incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. When the oligonucleotide is administered orally, it may be mixed with other
20 food forms and pharmaceutically acceptable flavor enhancers. When the oligonucleotide is administered enterally, they may be introduced in a solid, semi-solid, suspension, or emulsion form and may be compounded with any number of well-
25 known, pharmaceutically acceptable additives. Sustained release oral delivery systems and/or enteric coatings for orally administered dosage forms are also contemplated such as those described in U.S. Patent Nos. 4,704,295, 4,556,552, 4,309,404, and 4,309,406.

30 As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical formulation

or method that is sufficient to show a meaningful subject or patient benefit, i.e., a reduction in tumor growth or in the expression of proteins which cause or characterize the cancer. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

A "therapeutically effective manner" refers to a route, duration, and frequency of administration of the pharmaceutical formulation which ultimately results in meaningful patient benefit, as described above. In some embodiments of the invention, the pharmaceutical formulation is administered via injection, sublingually, colorectally, intradermally, orally, enterally or in bolus, continuous, intermittent, or continuous, followed by intermittent regimens.

The therapeutically effective amount of synthetic oligonucleotide administered in the method of the invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of synthetic oligonucleotide with which to treat each individual patient. Initially, the attending physician may administer low doses of the synthetic oligonucleotide and observe the

100-22656-102904

patient's response. Larger doses of synthetic oligonucleotide may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the dosages of the pharmaceutical compositions administered in the method of the present invention should contain about 0.1 to 100.0 mg/kg body weight per day, preferably 0.1 to 75.0 mg/kg body weight per day, more preferably, 1.0 to 50.0 mg/kg body weight per day, even more preferably, 1 to 25 mg/kg body weight per day, and even more preferably, 1 to 10 or 1 to 5.0 mg/kg body weight per day. The oligonucleotide is preferably administered at a sufficient dosage to attain a blood level of oligonucleotide from about 0.01 μ M to about 100 μ M. Preferably, the concentration of oligonucleotide at the site of aberrant gene expression should be from about 0.01 μ M to about 50 μ M, more preferably, from about 0.01 μ M to about 10 μ M, and most preferably from about 0.05 μ M to about 5 μ M. However, for localized administration, much lower concentrations than this may be effective, and much higher concentrations may be tolerated. It may be desirable to administer simultaneously or sequentially a therapeutically effective amount of one or more of the therapeutic compositions of the invention when individual as a single treatment episode.

It will be appreciated that the unit content of active ingredient or ingredients contained in an individual dose of each dosage form need not in

5 itself constitute an effective amount since the necessary effective amount can be reached by administration of a plurality of dosage units (such as suppositories, gels, or creams, or combinations thereof). In fact, multi-dosing (once a day) has been shown to significantly increase the plasma and tissue concentrations of MBO's (data not shown).

10 Administration of pharmaceutical compositions in accordance with invention or to practice the method of the present invention can be carried out in a variety of conventional ways, such as by oral ingestion, enteral, colorectal, or transdermal 15 administration, inhalation, sublingual administration, or cutaneous, subcutaneous, intramuscular, intraocular, intraperitoneal, or intravenous injection, or any other route of administration known in the art for administrating 20 therapeutic agents.

When the composition is to be administered orally, sublingually, or by any non-injectable route, the therapeutic formulation will preferably 25 include a physiologically acceptable carrier, such as an inert diluent or an assimilable edible carrier with which the composition is administered. Suitable formulations that include pharmaceutically acceptable excipients for 30 introducing compounds to the bloodstream by other than injection routes can be found in *Remington's Pharmaceutical Sciences* (18th ed.) (Genarro, ed. (1990) Mack Publishing Co., Easton, PA). The oligonucleotide and other ingredients may be

8986692, 862901

enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the individual's diet. The therapeutic compositions may be incorporated with excipients
5 and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. When the therapeutic composition is administered orally, it may be mixed with other food forms and
10 pharmaceutically acceptable flavor enhancers. When the therapeutic composition is administered enterally, they may be introduced in a solid, semi-solid, suspension, or emulsion form and may be compounded with any number of well-known,
15 pharmaceutically acceptable additives. Sustained release oral delivery systems and/or enteric coatings for orally administered dosage forms are also contemplated such as those described in U.S. Patent Nos. 4,704,295, 4,556,552, 4,309,404, and
20 4,309,406.

When a therapeutically effective amount of composition of the invention is administered by injection, the synthetic oligonucleotide will
25 preferably be in the form of a pyrogen-free, parenterally-acceptable, aqueous solution. The preparation of such parenterally-acceptable solutions, having due regard to ph, isotonicity, stability, and the like, is within the skill in
30 the art. A preferred pharmaceutical composition for injection should contain, in addition to the synthetic oligonucleotide, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium

100-999-2162-01

Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art. The pharmaceutical formulation can be administered in bolus, continuous, or intermittent dosages, or in a combination of continuous and intermittent dosages, as determined by the physician and the degree and/or stage of illness of the patient. The duration of therapy using the pharmaceutical composition of the present invention will vary, depending on the unique characteristics of the oligonucleotide and the particular therapeutic effect to be achieved, the limitations inherent in the art of preparing such a therapeutic formulation for the treatment of humans, the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.

To determine the preclinical range of anti-HIV activity of various oligonucleotides of the invention (see TABLE 2), evaluations were performed with Oligo 12 (having SEQ ID NO:1), Oligo 32 (SEQ ID NO:3) and Oligo 41 (SEQ ID NO:6). These evaluations were performed to determine the activity of these compounds against a variety of wild type and drug-resistant strains of HIV-1, including both laboratory derived and low passage,

5 clinical strains of virus and T-lymphocyte-tropic
and monocyte-macrophage-tropic viruses same as
these are listed below in TABLE 3.

5 **TABLE 3**
10 **BIOLOGICAL PROPERTIES OF CLINICAL STRAINS OF HIV-1**

| | <u>ISOLATE</u> | <u>TROPISM</u> | <u>AZT IC₅₀ (μM)</u> | <u>ddI IC₅₀ (μM)</u> | <u>SYNCYTIA</u> | <u>GROWTH</u> |
|----|----------------|----------------|---------------------------------|---------------------------------|-----------------|---------------|
| 10 | BAKI | L | 0.049 | 2.61 | SI | R/H |
| | SLKA | M | 0.025 | 0.32 | NSI | S/L |
| | WEJO | L | 0.056 | 2.18 | SI | R/H |
| | ROJO | L | 0.016 | 0.87 | SI | R/H |
| 15 | ROMA | M | 0.016 | 0.16 | SI | R/H |
| | STDA | L | 0.017 | 0.23 | SI | R/H |
| | WOME | L | 0.016 | 0.41 | SI | R/H |
| | VIHU | L | 0.016 | 1.21 | NSI | S/L |
| 20 | TEKI | L | 0.029 | 0.37 | NSI | S/L |
| | TEKI | M | 0.016 | 1.70 | NSI | S/L |
| | DEJO | L | 0.015 | ND | NSI | S/L |
| | BLCH | L | 0.010 | ND | NSI | S/L |
| 25 | RIARL | L | 0.010 | ND | NSI | S/L |

25 L - lymphocyte
M - macrophage
SI - syncytium inducing
NSI - non-syncytium inducing
R/H - rapid/high
S/L - slow/low

30 In addition, the activity of the compounds
was evaluated against HIV-2, and the toxicity of
oligo 41 was evaluated by a variety of methods in
35 infected and uninfected, established and fresh
human cells.

The initial experiment performed involved evaluation of Oligos 12, 32, and 41 against three laboratory strains of HIV-1 (IIIB, RF and SK1) and one strain of HIV-2 (ROD) in parallel with the 5 positive control compound ddC in the XTT-based anti-HIV assay. All these oligonucleotides are active against both HIV-1 and HIV-2. An enhanced level of activity was detected with these 10 compounds when evaluated against the HIV-2 strain ROD. Representative results are shown in FIG. 3.

In another experiment, the anti-HIV activity 15 of Oligos 12, 32, and 41 was evaluated against a variety of low passage, clinical strains of HIV-1 in fresh human peripheral blood mononuclear cells. These strains include viruses obtained from 20 pediatric patients attending the Children's Hospital University of Alabama at Birmingham as well as viruses representative of the various HIV-1 clades found throughout the world, shown below in TABLE 4.

TABLE 4

| | <u>VIRUS</u> | <u>CLADE</u> | <u>PHENOTYPE</u> | <u>COUNTRY</u> |
|----|--------------|--------------|------------------|----------------|
| 5 | 92RW009A | A | NSI | Rwanda |
| | 92UG029A | A | SI | Uganda |
| | 92BR021B | B | SI | Brazil |
| | 92TH026B | B | NSI | Thailand |
| | 92BR025C | C | NSI | Brazil |
| | 92UG021D | D | SI | Uganda |
| 10 | 92UG035D | D | NSI | Uganda |
| | 92TH022E | E | NSI | Thailand |
| | 93BR029F | F | NSI | Brazil |
| | 93BR020F | F | SI | Brazil |

In addition to these T-tropic strains, the activity of the compounds was also evaluated against the monocyte-macrophage strains BaL and ADA. Oligos 12 and 32 according to the invention, as well as Oligo 41 are active against low passage clinical T-tropic strains of HIV-1. The activity of the compounds varies from strain to strain. The compounds were not active against the monocyte-macrophage-tropic strains BaL and ADA.

In other studies, the anti-HIV activity of Oligos 12, 32, and 41 was evaluated against a variety of drug-resistant virus strains, including viruses resistant to nevirapine (N119), 3TC (M198I), protease inhibitors (JE105/R and KN1272/R) and AZT (4xAZT-R).

100-965692-2091
5 The results of these evaluations indicate
that these oligonucleotides remained active
against viruses resistant to nevirapine, 3TC and
the protease inhibitors, but were less active
against viruses with mutations conferring
resistance to AZT. An enhanced level of activity
was detected against the nevirapine-resistant
strain N119.

10 In yet another experiment, the toxicity of
Oligo 41 was evaluated in uninfected and HIV-1
infected fresh human peripheral blood mononuclear
cells, using a variety of quantitative endpoints.
Toxicity was evaluated using the tetrazolium dyes
XTT or MTT, trypan blue cell and cell viability
counting and the incorporation of tritiated
thymidine. Two replicate assays were performed.
In the first assay, Oligo 41 was used at a high
test concentration of 50 µg/ml and toxicity was
evaluated on day 7. No toxicity was detected by
any of the quantitative endpoints employed. A
second assay was performed to further evaluate
toxicity at higher compound concentration and with
longer exposure to the compound. In this assay,
25 employing a high test concentration of 150 µg/ml
and extending the time of drug exposure from 7
days until 14 days, once again no toxicity was
detected.

30 In another set of experiments, the
bioavailability of Oligo 12 was examined *in vivo* was
found to be intravenously and orally bioavailable
to rats and monkeys after a single dose.

406290-26996800
In addition, synthetic oligonucleotides
systemically administered to pregnant murine
females were found to cross the placenta and be
available in the blood of embryos *in utero*. Thus, it
5 is contemplated that oligonucleotides of the
invention be used in methods of treating human
fetuses and mothers harboring HIV.

In order to determine if the oligonucleotide
10 of the invention administered according to the
method of the invention is absorbed into body
tissues, and if so, in which tissues absorption
occurs, the following study was performed.
Samples of various body tissues from treated
15 monkeys and rats were analyzed for radioactivity
at increasing hours after intravenous or oral
administration of a radioactively labelled
oligonucleotide specific for HIV. This
oligonucleotide was found to be absorbed through
20 the gastrointestinal tract and accumulated in
various organs and tissues.

To evaluate the chemical form of
radioactivity in plasma HPLC is used to
25 demonstrate the presence of both intact
oligonucleotide as well as metabolites various
hours after oral administration. Intact
oligonucleotide may also be detected in liver
various hours after administration. Further
30 evidence to support the absorption of the
oligonucleotide may come from urine sample
analysis after radioactively labelled *gag*-specific
oligonucleotide was orally administered. That the
oligonucleotide continues to be excreted in the

urine over time following the administration of radiolabelled oligonucleotide implies that other tissues had absorbed it, and that the body was capable of absorption for an extended period of time.

The following examples illustrate the preferred modes of making and practicing the present invention, but are not meant to limit the scope of the invention since alternative methods may be utilized to obtain similar results.

EXAMPLE 1

Synthesis and Purification of Oligonucleotides

Oligonucleotide phosphorothioates were synthesized using an automated DNA synthesizer (Model 8700, Biosearch, Bedford, MA) using a beta-cyanoethyl phosphoramidate approach on a 10 micromole scale. To generate the phosphorothioate linkages, the intermediate phosphite linkage obtained after each coupling was oxidized using 3H, 1,2-benzodithiole-3H-one-1,1-dioxide (see Beaucage, in *Protocols for Oligonucleotides and Analogs: Synthesis and Properties*, Agrawal (ed.), (1993) Humana Press, Totowa, NJ, pp. 33-62).

Hybrid oligonucleotides were synthesized similarly, except that segments containing 2'-O-methylribonucleotides were assembled using 2'-O-methylribonucleoside phosphoramidite, followed by oxidation to a phosphorothioate or phosphodiester linkage as described above. Deprotection and purification of oligonucleotides was carried out

according to standard procedures, (see Padmapriya et al. (1994) *Antisense Res. & Dev.* 4:185-199).

5 **EXAMPLE 2**

Propagation and Quantitation of Cell Lines
and Virus Stocks

10 A. Cells

15 The CEM-SS cell line (Southern Research Institute-Frederick Research Center, Frederick, MD) is highly susceptible to infection with HIV, rapidly form multinucleated syncytia, and are eventually killed by HIV. The cells were maintained ($2-7 \times 10^5$ cells per ml) in RPMI 1640 tissue culture medium supplemented with 10% fetal bovine serum, glutamine, and antibiotics, and were passaged twice weekly at 1:20 dilution. Passage number was logged each week. Cells were discarded after twenty weeks of passage and fresh CEM-SS cells thawed and utilized in the assay. Stocks of CEM-SS cells were frozen in liquid nitrogen in 1 ml NUNC vials in 90% fetal calf serum and 10% 20 dimethyl sulfoxide (DMSO). Following thawing, CEM-SS cells were routinely ready to be utilized in the primary screen assay after two weeks in culture. Prior to replacing a late passage cell line, the new CEM-SS cells were tested in the 25 screening assay protocol utilizing the current stock of infectious virus and AZT. If the infectivity of the virus was significantly different on the new cells or if AZT appeared less active than expected the new cells were not

09895592-062901

entered into the screening program. Mycoplasma testing was routinely performed on all cell lines.

5 Other viral isolates tested included the following drug resistant strains.

10 The N119 isolate was derived *in vitro* by culture of the clinical strain A018 in the presence of the nonnucleoside reverse transcriptase inhibitor nevirapine. This isolate was obtained from the NIAID AIDS research and Reference Reagent Program (catalog #1392). The isolate possesses one mutation in the reverse transcriptase (Y181C) and we have found the 15 isolate to be extremely cytopathic to T cells such as CEM-SS and MT2 (Richman et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:11241). The 3TC/M1841 isolate was selected *in vitro* using the wild type IIIB strain of virus and sequential passage of the virus in the presence of increasing drug concentration in 20 CEM-SS cells (Buckheit Jr. et al. (1996) *Antimicrob. Chem. Chemother.* 7:243-252). The JE 105/R isolate was derived from sequential passage of IIIB in the presence of a protease inhibitor. This isolate 25 possesses the I84V and S37N amino acid changes in the protease. The KNI272/R isolate was derived from sequential passage of IIIB in the presence of the protease inhibitor KNI272. The isolate possesses three amino acid changes in the 30 protease, F53L, A71V and T80I. The 4xAZT-Ri isolate was obtained by site-directed mutagenesis through introduction of four amino acid changes in the reverse transcriptase of the NL4-3 wild type

virus. The four amino acid changes are D67N, K70R, T215Y, and K219Q.

B. Virus

Virus pools (Southern Research Institute-Frederick Research Center, Frederick MD) were prepared and titrated in CEM-SS cells, placed in 5 ml aliquots, and frozen at -135°C. After thawing, unused virus is discarded to avoid changes in infectious titer. Virus pools were prepared by the acute infection of 5×10^5 CEM-SS cells with HIV in a volume of 200 μ l at a multiplicity of infection determined to give complete cell killing at day 7 post-infection (approximately 0.05 for the III_b isolate of HIV-1 and 0.01 for the RF isolate of HIV-1).

C. Assay

Infection was allowed to proceed for one hour at 37°C, after which the cells were transferred to a T25 flask and the volume increased to 2 ml. On day 1 post-infection the volume was brought to 5 ml and on day 2 the volume was increased to 10 ml. Beginning on day 4, the cells were pelleted, the supernatant saved, and the cells resuspended in a fresh 10 ml aliquot of tissue culture medium. Complete medium changes on a daily basis, rather than allowing growth of the cells in the medium for longer periods of time, allowed the virus inoculum utilized in the primary screen to remain relatively undepleted of nutrients when it is used to infect cells. The staining reaction utilized

09896692-062901

(XTT, see method below) required that the glucose concentration remain high (161). Wells depleted of glucose by cell growth will not permit metabolic conversion of the tetrazolium dye to the formazan product.

5 Cell-free supernatants from the acutely infected cells were saved on day 4, day 5, day 6, and day 7. An aliquot of supernatant was saved
10 separately on each day for use in titer determination. Titer determinations included reverse transcriptase activity assay (see below), endpoint titration or plaque assay (CEM-SS) quantification of infectious particles (see
15 below), and quantification of cell killing kinetics. ,

20 It has been determined that peak levels of infectious virus are produced in the acutely infected cultures as the viability of the cells falls through the 50% level. Since the primary screening assay quantifies the protective effects of a compound by its ability to inhibit HIV-induced cytopathic effects, the quantity of virus required to kill CEM-SS cells in 6 days was routinely utilized to determine the amount of virus required per well in the primary screening assay. Each of the daily pools was titrated in the primary screening tetrazolium dye XTT assay
25 protocol (see below) by performing two-fold dilutions of the virus beginning at a high test concentration of 50 μ l of virus per well. The XTT staining method was utilized to determine the exact amount of virus required to kill all of the
30

CEM-SS cells in each well and this minimum amount of virus was utilized for performance of all primary testing. Identical methods were utilized to prepare all virus isolates utilized, including 5 laboratory-derived strains of HIV-1, HIV-2 and SIV. Clinical isolates utilized were passaged in fresh human cells. The methods for the growth of these cells and the production of virus pools is described below.

10

EXAMPLE 3

Microtiter Antiviral XTT Assay

A. Cell Preparation:

15

CEM-SS cells (AIDS Research and Reference Reagent Program, NIH) or other established human T cell lines used in these experiments were passaged in T-150 flasks for use in the assay. On the day preceding the assay, the cells were split 1:2 to assure they would be in an exponential growth phase at time of infection. On the day of assay the cells were washed twice with tissue culture medium and resuspended in fresh tissue culture medium. Total cell and viability counting was performed using a hemacytometer and trypan blue dye exclusion. Cell viability was greater than 95% for the cells to be utilized in the assay. The cells were pelleted and resuspended at 2.5×10^4 cells per ml in tissue culture medium. Cells were added to the drug-containing plates in a volume of 50 μ l.

09899692.062901

B. Virus Preparation

A pretitered aliquot of virus was removed
from the freezer -80°C) and allowed to thaw slowly
5 to room temperature in a biological safety
cabinet. The virus was resuspended and diluted
into tissue culture medium such that the amount of
virus added to each well in a volume of 50 μ l will
be the amount determined to give complete cell
10 killing at 6 days post-infection. In general the
virus pools produced with the IIIB isolate of HIV
required the addition of 5 μ l of virus per well.
15 Pools of RF virus were five to ten-fold more
potent, requiring 0.5 to 1 μ l per well. TCID₅₀
calculation by endpoint titration in CEM-SS cells
indicated that the multiplicity of infection of
these assays ranged from 0.005 to 2.5.

C. Plate Format

20 Each plate contained cell control wells
(cells only), virus control wells (cells plus
virus), drug toxicity control wells (cells plus
drug only), drug colorimetric control wells (drug
25 only) as well as experimental wells (drug plus
cells plus virus).

D. XTT Staining of Screening Plates

30 After 6 days of incubation at 37°C in a 5%
CO₂ incubator, the test plates were analyzed by
staining with the tetrazolium dye XTT. XTT-
tetrazolium is metabolized by the mitochondrial
enzymes of metabolically active cells to a soluble

formazan product, allowing the rapid quantitative analysis of the inhibition of HIV-induced cell killing by anti-HIV test substances. On day 6 post-infection plates were removed from the 5 incubator and observed. The use of round bottom microtiter plates allows rapid macroscopic analysis of the activity of a given test compound by the evaluation of pellet size. The results of the macroscopic observations were confirmed and 10 enhanced by further microscopic analysis.

XTT solution was prepared daily as a stock of 1 mg/ml in PBS. Phenazine methosulfate (PMS) solution was prepared at 15 mg/ml in PBS and 15 stored in the dark at -20°C. XTT/PMS stock was prepared immediately before use by diluting the PMS 1:100 into PBS and adding 40 μ l per ml of XTT solution. Fifty microliters of XTT/PMS was added to each well of the plate and the plate was 20 incubated for an additional 4 hours at 37°C. Adhesive plate sealers were used in place of the lids, the sealed plate was inverted several times to mix the soluble formazan product and the plate was read spectrophotometrically at A450 nm with a 25 Molecular Devices Vmax plate reader. Using an in-house computer program % CPE (cytopathic effect) reduction, % cell viability, $IC_{25,50 \pm 95\%}$, $TC_{25,50 \pm 95\%}$ and other indices were calculated and the graphic results summary was displayed.

30

EXAMPLE 4

Reverse Transcriptase Activity Assay

A microtiter based reverse transcriptase (RT) reaction was utilized (Buckheit et al (1991) *AIDS Research and Human Retroviruses* 7:295-302). Tritiated thymidine triphosphate (NEN) (TTP) was resuspended in distilled H₂O at 5 Ci/ml. Poly rA and oligo dT were prepared as a stock solution which was kept at -20°C. The RT reaction buffer was prepared fresh on a daily basis and consists of 125 µl 1 M EGTA, 125 µl dH₂O, 125 µl Triton X-100, 50 µl 1 M Tris (pH 7.4), 50 µl 1 M DTT, and 40 µl 1 M MgCl₂. These three solutions were mixed together in a ratio of one part distilled water. Ten microliters of this reaction mixture was placed in a round bottom microtiter plate and 15 µl of virus containing supernatant was added and mixed. The plate was incubated at 37°C and incubated for 60 minutes. Following reaction, the reaction volume was spotted onto filter mats, washed 6 times for 5 minutes each in a 5% sodium phosphate buffer, two times for 1 minute each in distilled water, two times for 1 minute each in 70% ethanol, and then dried. The dried filter mat was placed in a plastic sample bag, Betaplate scintillation fluid was added and the bag was heat-sealed. Incorporated radioactivity was quantified utilizing a Wallac Microbeta, scintillation counter (Gaithersburg, MD).

EXAMPLE 5
p24 ELISA

ELISA kits were purchased from Coulter
5 (Miami, FL). The assay is performed according to
the manufacturer's recommendations. Prior to
ELISA analysis the reverse transcriptase activity
assays (described above) were routinely performed
and used the values for incorporated radioactivity
10 in the RT activity assay to determine the dilution
of our samples requires for the ELISA. Standard
curves were constructed so that the dilutions of
virus to be used in the p24 ELISA could be
accurately determined from the RT activity assay.
15 Control curves were generated in each assay to
accurately quantify the amount of capsid protein
in each sample. Data was obtained by
spectrophotometric analysis at 450 nm using a
plate reader. Molecular Devices Vmax P24
20 (Sunnydale, CA) concentrations were calculated
from the optical density values by use of the
Molecular Devices (San Hose, CA) software package
Soft Max.

25 EXAMPLE 6
Infectious Particles

Infectious virus particles were qualified
utilizing the CEM-SS plaque assay as described by
30 Nara et al. (*Nature* (1988) 332:469-470). Flat
bottom 96-well microtiter plates were coated with
50 μ l of poly-L-lysine (Sigma. St. Louis, MO) at
50 μ g/ml for 2 hours at 37°C. The wells were then
washed with PBS and 2.5×10^5 CEM-SS cells were

placed in the microtiter well where they became
fixed to the bottom of the plate. Enough cells
were added to form a monolayer of CEM-SS cells in
each well. Virus containing supernatant was added
5 from each well of the XTT plate, including virus
and cell controls and each serial dilution of the
test substance. The number of syncytia were
qualified in the flat-bottom 96-well microtiter
plate with an Olympus CK2 inverted microscope at 4
10 days following infection. Each syncytium resulted
from a single infectious HIV virion.

EXAMPLE 7

Anti-HIV Activity in Fresh Human Cells

15 A. Assay in Fresh Human T-Lymphocytes

Fresh human peripheral blood lymphocytes
(PBL) were isolated from voluntary Red Cross
20 donors, seronegative for HIV and HBV.
Leukophoresed blood was diluted 1:1 with
Dulbecco's phosphate buffered saline (PBS),
layered over 14 ml of Ficoll-Hypaque density
gradient in a 50 ml centrifuge tube. Tubes were
25 then centrifuged for 30 minutes at 600 X g.
Banded PBLs were gently aspirated from the
resulting interface and subsequently washed 2X
with PBS by low speed centrifugation. After final
wash, cells were enumerated by trypan blue
30 exclusion and re-suspended at 1×10^7 /ml in RPMI
1640 with 15% Fetal Bovine Serum (FBS), 2 mM L-
glutamine, 4 mg/ml PHA-P and allowed to incubate
for 48 - 72 hours at 37°C. After incubation, PBLs
were centrifuged and reset in RPMI 1640 with 15%

106290-26996860
5 FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100
μg/ml streptomycin, 10 μg/ml gentamycin, and 20
U/ml recombinant human IL-2. PBLs were maintained
in this medium at a concentration of 1-2 x 10⁶/ml
with bi-weekly medium changes, until use in assay
protocol.

10 For the PBL assay, PHA-P stimulated cells
from at least two normal donors were pooled, set
in fresh medium at 2 x 10⁶/ml, and plated in the
interior wells of a 96 well round bottom
microplate at 50 μL/well. Test drug dilutions
were prepared at a 2X concentration in microtiter
tubes, and 100 μl of each concentration was placed
15 in appropriate wells in a standard format. Fifty
microliters of a predetermined dilution of virus
stock was placed in each test well. Wells with
cells and virus alone were used for virus control.
Separate plates were identically set without virus
20 for drug cytotoxicity studies using an XTT assay
system.

25 In the standard PBL assay (MOI: 0.2), the
assay was ended on day 7 following collection of
cell free supernatant samples for reverse
transcriptase activity assay. In the low MOI PBL
assay (MOI: 0.02), supernatant samples were
30 collected on day 6, day 11, and day 14 post-
infection and analyzed for RT activity. Tritiated
thymidine triphosphate (NEN) (TTP) was resuspended
in distilled H₂O at 5 Ci/ml. Poly rA and oligo dT
were prepared as a stock solution which was kept
at -20°C. The RT reaction buffer was prepared
fresh on a daily basis and consists of 125 μl 1 M

05896692-062901

DTT, and 40 μ l 1 M MgCl₂. These three solutions were mixed together in a ratio of 2 parts TTP, 1 part poly rA:oligo dT, and 1 part reaction buffer. Ten microliters of this reaction mixture was
5 placed in a round bottom microtiter plate and 15 μ l of virus containing supernatant was added and mixed. The plate was incubated at 37°C in a water bath with a solid support to prevent submersion of the plate and incubated for 60 minutes. Following
10 reaction, the reaction volume was spotted onto pieces of DE81 paper, washed 5 times for 5 minutes each in a 5% sodium phosphate buffer, 2 times for 1 minute each in distilled water, 2 times for 1 minute each in 70% ethanol, and then dried. Opti-
15 Fluor O was added to each sample and incorporated radioactivity was quantified utilizing a liquid scintillation counter, (Wallac 1450 Microbeta plus, Gaithersburg, MD).

20 Tritiated thymidine incorporation was measured in parallel cultures at day 7. Each well was pulsed with 1 μ Ci of tritiated thymidine and the cells were harvested 18 hours later with a Skatron cell harvester onto glass fiber filter
25 papers. The filters were dried, placed in a scintillation vial with 1 ml of scintillation cocktail and incorporated radioactivity was quantified on a liquid scintillation counter (e.g., Packard Tri-Carb 1900 TR450).

30

B. Assay in Fresh Human Monocyte-Macrophages

For isolation of adherent cells, 3 \times 10⁶ non-PHA stimulated peripheral blood cells were

resuspended in Hanks buffered saline (with calcium and magnesium) supplemented with 10% human AB serum. The cells were placed in a 24-well microtiter plate at 37°C for 2 hours. Non-adherent cells were removed by vigorously washing six times. The adherent cells were cultured for 7 days in RPMI 1640 tissue culture medium with 15% fetal bovine serum. The cultures were carefully monitored for confluence during this incubation period. Infection of the cells was performed with the monocytotropic HIV-1 strains BaL or ADA and the matched pair of AZT-sensitive and AZT-resistant virus isolates. Each of these virus isolates was obtained from the NIAID AIDS Research and Reference Reagent Program. High titer pools of each of these viruses have been harvested from infected cultures of peripheral blood adherent cells and frozen in 1.0 ml aliquots at -80°C. Monocyte-macrophage monolayers were infected at an MOI of 0.1. Compounds to be evaluated in the monocyte-macrophage assay are added to the monolayers shortly before infection in order to maximize the potential for identifying active compounds.

25 At 2 days post-infection, the medium was
decanted and the cultures washed twice with
complete medium in order to remove excess virus.
30 Fresh medium alone or medium containing the
appropriate concentrations of drugs was added and
incubation continued for an additional 5 days.
XTT-tetrazolium or trypan blue exclusion assays
(for cell viability) and HIV p24 ELISA assays (for
production of p24 core antigen) were performed on

Day 7 post-infection. ELISA kits were purchased from Coulter. The assay is performed according to the manufacturer's recommendations. Control curves are generated in each assay to accurately 5 quantify the amount of capsid protein in each sample. Data was obtained by spectrophotometric analysis at 450 nm using a plate reader (Molecular Devices Vmax). P24 concentrations were calculated from the optical density values by use of the 10 Molecular Device software package Soft Max.

EXAMPLE 8

Inhibition of Acute Infection of MT-4 Cells

15 CPE based infection experiments were performed using MT-4 cells (Pauwels et al. (1988) *J. Virol. Meth.* 20:309; Papp et al. (1997) *AIDS Research and Human Retroviruses In Press*). MT-4 cells were obtained from the AIDS Research and Reference Reagent Bank, 20 Division of AIDS, NIAID, NIH contributed Dr. Richman (Pauwels et al. (1988) *J. Virol. Meth.* 20:309). T-lymphoid H9 (HUT-78) cells were obtained from Dr. Robert Gallo, National Cancer Institute, Bethesda, MD (Popovic et al. (1984) *Science* 224:497; 25 Gazdar et al. (1980) *Blood* 55:409). Cell cultures were maintained in RPMI 1640 medium (GIBCO Laboratories, Grand Island, NY) supplemented with 20% (H9 cells), or 10% (MT-4 cells) heat- 30 inactivated fetal bovine serum (Sigma Chemical Co., St. Louis, MO) 250 units/ml penicillin, 250 µg/ml streptomycin, 2 mM l-glutamine, and 10 mM HEPES(N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) buffer (complete medium) at

37°C in 5% CO₂. HIV-1 IIB was originally obtained from Dr. Robert Gallo, National Cancer Institute (Popovic (1984) *Science* 224:497). Virus stocks of HIV-1 were prepared from cell-free filtered supernatant of chronically infected H9 cultures by the shaking method as previously described by Vujoie et al. (*J. Infectious Diseases* (1988) 157:1047).

Experiments were performed under two sets of conditions. Dilutions of hybrid oligonucleotides according to the invention having SEQ ID NO:1 were prepared in 96-well plates and infections were performed either in the presence of inhibitors, by adding MT-4 cells and a TCID_{CPE-90%} concentration of HIV-_{H9B} directly to the wells, or by infecting MT-4 cells for 4 hours at 37°C in the absence of inhibitors, washing to remove non-adsorbed virus, then adding the infected cells to wells containing inhibitors. The cultures were incubated for 6 days and CPE measured using the MTT dye method. (Rapid, (1983) *J. Immunolog. Meth.* 65:55).

The results demonstrate that an oligonucleotide of the invention inhibits HIV-1 infection when added to cells during viral infection (FIG. 1) or post-viral adsorption (FIG. 2).

EXAMPLE 9

Measurement of Orally Administered Oligonucleotide

A. Animals and Treatment

Male Sprague-Dawley rats (100-120 g, Harlan Laboratories, Indianapolis, IN) and male CD-/F2 mice (25 ± 3 g, Charles River Laboratory, Wilmington, MA) are used in the study. The 5 animals are fed with commercial diet and water *ad libitum* for 1 week prior to the study.

Unlabelled and ³⁵S-labelled oligonucleotides are dissolved in physiological saline (0.9% NaCl) 10 in a concentration of 25 mg/ml, and are administered to the fasted animals via gavage at the designated dose (30-50 mg/kg for rats and 10 mg/kg for mice). Doses are based on the pretreatment body weight and rounded to the 15 nearest 0.01 ml. After dosing, each animal is placed in a metabolism cage and fed with commercial diet and water *ad libitum*. Total voided urine is collected and each metabolism cage is then washed following the collection intervals. 20 Total excreted feces is collected from each animal at various timepoints, and feces samples are homogenized prior to quantitation of radioactivity. Blood samples are collected in heparinized tubes from animals at the various 25 timepoints. Plasma is separated by centrifugation. Animals are euthanized by exsanguination under sodium pentobarbital anesthesia at various times (i.e., 1, 3, 6, 12, 24, and 48 hr; 3 animals/time point). Following 30 euthanasia, the tissues are collected from each animal. All tissues/organs are trimmed of extraneous fat or connective tissue, emptied and cleaned of all contents, individually weighed, and the weights recorded.

To quantitate the total absorption of the hybrid oligonucleotide, two additional groups of animals (3/group) for each test oligonucleotide are treated using the same procedure as above.

5 Animals are killed at 6 or 12 hr post dosing, and the gastrointestinal tract is then removed. Radioactivities in the gastrointestinal tract, feces, urine, plasma, and the remainder of the body is determined separately. Total recovery of 10 radioactivity is also determined to be $95 \pm 6\%$. The percentage of the absorbed hybrid oligonucleotide-derived radioactivity is determined by the following calculation:
(total radioactivity in the remainder of the body
+ total radioactivity in urine) ÷
(total radioactivity in the gastrointestinal tract, feces, urine, plasma, and the remainder of the body).

15 B. Radioactive Labelling of Oligonucleotide

To obtain ^{35}S -labelled oligonucleotide, synthesis is carried out in two steps. The first nucleotides of the oligonucleotide sequence from 20 its 3'-end are assembled using the β -cyanoethyl-phosphoramidite approach (see, Beaucage in *Protocols for Oligonucleotides and Analogs* (Agrawal, ed.), Humana Press, (1993), pp. 33-61). The last nucleotides 25 are assembled using the H-phosphonate approach (see, Froehler in *Protocols for Oligonucleotides and Analogs* (Agrawal, ed.) Humana Press, 1993, pp. 63-80). Controlled pore glass (CPG) support-bound 30 oligonucleotide (30 mg of CPG; approximately 1 μM) containing five H-phosphonate linkage is oxidized

with $^{35}\text{S}_8$ (4 mCi, 1 Ci/mg, Amersham; 1 Ci = 37 GBq) in 60 ml carbon disulfide/pyridine/triethylamine (10:10:1). The oxidation reaction is performed at room temperature for 1 hr with occasional shaking.

5 Then 2 μl , 5 μl , and 200 μl of 5% cold sulfur ($^{32}\text{S}_8$) in same solvent mixture is added every 30 min to complete the oxidation. The solution is removed and the CPG support is washed with carbon disulfide/pyridine/ triethylamine (10:10:1) (3 x 10 500 μl) and with acetonitrile (3 x 700 μl). The product is deprotected in concentrated ammonium hydroxide (55°C, 14 hr) and evaporated. The resultant product is purified by polyacrylamide gel electrophoresis (20% polyacrylamide containing 15 7 M urea). The desired band is excised under UV shadowing and the PS-oligonucleotide was extracted from the gel and desalted with a Sep-Pak C18 cartridge (Waters) and Sephadex G-15 column.

20 C. Total Radioactivity Measurements

The total radioactivities in tissues and body fluids is determined by liquid scintillation spectrometry (LS 6000TA, Beckman, Irvine, CA). In brief, biological fluids (plasma, 50-100 μl ; urine, 50-100 μl) are mixed with 6 ml scintillation solvent (Budget-Solve, RPI, Mt. Prospect, IL) to determine total radioactivity. Feces are ground and weighed prior to being 25 homogenized in a 9-fold volume of 0.9% NaCl saline. An aliquot of the homogenate (100 μl) is mixed with solubilizer (TS-2, RPI, Mt. Prospect, IL) and then with scintillation solvent (6 ml) to permit quantitation of total radioactivity.

Following their removal, tissues are immediately blotted on Whatman No. 1 filter paper and weighed prior to being homogenized in 0.9% NaCl saline (3-5 ml per gram of wet weight). The resulting homogenate (100 μ l) is mixed with solubilizer (TS-2, RPI, Mt. Prospect, IL) and then with scintillation solvent (6 ml) to determine total radioactivity. The volume of 0.9% NaCl saline added to each tissue sample is recorded. The homogenized tissues/organs are kept frozen at $\leq 70^{\circ}\text{C}$ until the use for further analysis.

D. HPLC Analysis

The radioactivity in urine is analyzed by paired-ion HPLC using a modification of the method described essentially by Sands et al. (*Mol. Pharm.* (1994) 45:932-943). Urine samples are centrifuged and passed through a 0.2- μm Acro filter (Gelman, Ann Arbor, MI) prior to analysis. Hybrid oligonucleotide and metabolites in plasma samples are extracted using the above methods in sample preparation for PAGE. A Microsorb MV-C4 column (Rainin Instruments, Woburn, MA) is employed in HPLC using a Hewlett Packard 1050 HPLC with a quaternary pump for gradient making. Mobile phase includes two buffers; Buffer A was 5 mM-A reagent (Waters Co., Bedford, MA) in water and Buffer B is 4:1 (v/v) Acetonitrile (Fisher)/water. The column is eluted at a flow rate of 1.5 ml/min, using the following gradient: (1) 0-4 min, 0% buffer B; (2) 4-15 min 0-35% Buffer B; and (3) 15-70 min 35%-80% Buffer B. The column is equilibrated with Buffer A for at least 30 min prior to the next run. By

using a RediFrac fraction collector (Pharmacia LKB Biotechnology, Piscataway, NJ), 1-min fractions (1.5 ml) are collected into 7-ml scintillation vials and mixed with 5 ml scintillation solvent to 5 determine radioactivity in each fraction.

E. Analysis of Test Oligonucleotides

10 Polyacrylamide gel electrophoresis (PAGE) of oligonucleotides and its metabolites is carried out by known and established methods. Plasma and tissue homogenates are incubated with proteinase K (2 mg/ml) in extraction buffer (0.5% SDS/10 mM NaCl/20 mM Tris-HCl, pH 7.6/10 mM EDTA) for 1 hr 15 at 60°C. The samples are then extracted twice with phenol/chloroform (1:1, v/v) and once with chloroform. After ethanol precipitation, the extracts are analyzed by electrophoresis in 20% polyacrylamide gels containing 7 M urea. Urine 20 samples are filtered, desalted and then analyzed by PAGE. The gels are fixed in 10% acetic acid/10% methanol solution and then dried before autoradiography.

25 EQUIVALENTS

Those skilled in the art will recognize, or 30 be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific substances and procedures described herein. Such equivalents are considered to be within the scope of this invention, and are covered by the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Agrawal, Sudhir

(ii) TITLE OF INVENTION: NOVEL HIV-SPECIFIC SYNTHETIC OLIGONUCLEOTIDES AND METHODS OF THEIR USE

(iii) NUMBER OF SEQUENCES: 6

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Hale and Dorr LLP
(B) STREET: 60 State Street
(C) CITY: Boston
(D) STATE: Massachusetts
(E) COUNTRY: USA
(F) ZIP: 02109

(v) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US
(B) FILING DATE:

(vii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Kerner, Ann-Louise
(B) REGISTRATION NUMBER: 33,523
(C) REFERENCE/DOCKET NUMBER: HYZ-069

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 617-526-6000
(B) TELEFAX: 617-526-5000

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA/RNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

UCGCACCCAT CTCTCTCCUU C

21

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

TCGCACCCAT CTCTCTCCTT C

21

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA/RNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CGCACCCATC TCTCTCCUUC U

21

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: YES
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CGCACCCATC TCTCTCCTTC T

21

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TCGCACCCAT CTCTCTCCTT CT

22

(2) INORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA/RNA
- (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: YES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TCGCACCCAT CTCTCTCCTT C

21

0989562 - 0989560